Cargando…
Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway
Immune checkpoint inhibitors such as monoclonal antibodies (mAbs) are amongst the most important breakthroughs in cancer therapeutics. However, high cost and short acting time limits its affordability and clinical application. Therefore, an economical and durable alternative is urgently needed. Prev...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875535/ https://www.ncbi.nlm.nih.gov/pubmed/35214622 http://dx.doi.org/10.3390/vaccines10020163 |